Dulaglutide to Liraglutide Dose Conversion Guide
Medically reviewed by Lauren Okafor | MD, The Frank H Netter MD School of Medicine, Loyola University Medical Center on July 21st, 2026.
Published on July 22nd, 2026. Updated on July 22nd, 2026.
Key takeaways
No direct mg-to-mg conversion exists between dulaglutide and liraglutide because one is dosed weekly and the other daily, making total weekly exposure the more relevant comparison.
The most commonly referenced bridge is dulaglutide 1.5 mg weekly to liraglutide 1.2 to 1.8 mg daily, though individual patient factors always apply.
Liraglutide requires a mandatory 4-week titration starting at 0.6 mg daily, even for patients who were already stable on dulaglutide.
Higher dulaglutide doses like 3 mg or 4.5 mg weekly cannot be fully replicated by liraglutide, which has a 1.8 mg daily ceiling for the diabetes indication.
A prescriber review is essential before switching because renal function, cardiovascular history, injection technique, and insurance coverage all influence the safest approach.
Why Patients Switch Between These Two GLP-1 Medications
Dulaglutide, sold as Trulicity, and liraglutide, sold as Victoza, belong to the same drug class: GLP-1 receptor agonists. Both lower blood sugar by stimulating insulin release, slowing gastric emptying, and reducing glucagon secretion. Despite sharing a mechanism, they are not interchangeable at face value.
The most common reasons patients switch from dulaglutide to liraglutide include formulary changes by an insurance plan, cost differences, side effect profiles, or a shift in overall care strategy. Sometimes a prescriber may prefer liraglutide for specific clinical reasons, such as existing familiarity with the drug or patient-specific cardiovascular data. Whatever the reason, understanding the differences before making the switch helps patients and caregivers ask the right questions and set realistic expectations.
How the Two Drugs Are Structured Differently
The most important structural difference is dosing frequency. Dulaglutide is injected once weekly at doses of 0.75 mg, 1.5 mg, 3 mg, or 4.5 mg. Liraglutide is injected once daily at 0.6 mg (starter dose), 1.2 mg, or 1.8 mg, with 1.8 mg being the maximum approved dose for type 2 diabetes.
Because one drug is dosed weekly and the other daily, comparing a single-dose milligram number is misleading. A more useful frame is total weekly exposure. Liraglutide at its maximum diabetes dose of 1.8 mg daily represents approximately 12.6 mg per week. That context helps illustrate why a direct mg-to-mg switch is not clinically appropriate and why the conversion requires medical judgment rather than simple arithmetic.
The administration devices also differ. Dulaglutide uses a single-use auto-injector designed for once-weekly self-injection. Liraglutide uses a multi-dose pen requiring daily injection. For some patients, switching from a weekly to a daily injection routine may affect adherence, which is a factor worth discussing with a prescriber before committing to the change.
Approximate Conversion Reference Points
No FDA-approved conversion table exists for switching between these two medications. Clinicians rely on pharmacodynamic equivalence studies, prescriber experience, and individual patient data to guide the transition. The following reference points reflect general clinical consensus, not official guidelines.
Feature |
Dulaglutide (Trulicity) |
Liraglutide (Victoza) |
|---|---|---|
Dosing frequency |
Once weekly |
Once daily |
Available doses (diabetes) |
0.75 mg, 1.5 mg, 3 mg, 4.5 mg |
0.6 mg, 1.2 mg, 1.8 mg |
Maximum diabetes dose |
4.5 mg weekly |
1.8 mg daily |
Titration required |
Recommended step-up |
Mandatory 4-week starter at 0.6 mg |
Cardiovascular outcome trial |
REWIND |
LEADER |
Administration device |
Single-use auto-injector |
Multi-dose pen |
As a general bridge, dulaglutide 0.75 mg weekly is often considered roughly comparable in glucose-lowering effect to liraglutide 0.6 to 1.2 mg daily. Dulaglutide 1.5 mg weekly is most commonly bridged to liraglutide 1.2 to 1.8 mg daily. Importantly, higher dulaglutide doses of 3 mg or 4.5 mg weekly have no established liraglutide equivalent because 1.8 mg daily is the ceiling for the diabetes indication. Patients on those higher doses should have a careful conversation with their prescriber about managing any potential gap in glycemic coverage.
What to Expect During the Transition Period
Even patients who tolerated dulaglutide without significant GI discomfort may experience nausea, vomiting, or digestive upset when starting liraglutide. The daily dosing pattern creates a different exposure profile, and the gut may respond accordingly in the early weeks.
Liraglutide always requires a 4-week titration period starting at 0.6 mg daily before advancing to a therapeutic dose, regardless of prior GLP-1 experience. This step is not optional. Skipping it increases the risk of GI side effects and is not recommended by prescribers.
Blood glucose monitoring should be more frequent in the first 4 to 8 weeks after switching. Weight and HbA1c responses may also differ between the two agents. Some patients find their blood sugar control shifts modestly during the transition, which may prompt adjustments to other medications in their diabetes regimen. Staying in close contact with a care team during this window helps catch any changes early.
Key Clinical Considerations Before Making the Switch
Several patient-specific factors should be reviewed before switching from dulaglutide to liraglutide.
Renal function is one consideration. While both drugs are used in patients with chronic kidney disease, they have slightly different renal data profiles, and a prescriber needs to confirm the appropriateness of liraglutide for a given patient's kidney status.
Cardiovascular history is another. Both dulaglutide and liraglutide have cardiovascular outcome trial data, but the trial populations differed. The LEADER trial studied liraglutide and the REWIND trial studied dulaglutide, and the patient characteristics in each study varied. For patients with established cardiovascular disease or high cardiovascular risk, a prescriber may weigh this data differently depending on the individual's profile.
Insurance and cost are often the practical trigger for switching. Before filling the first liraglutide prescription, patients should confirm that their plan covers liraglutide at the therapeutic dose, not only the starter dose. Coverage at the 0.6 mg level without coverage at 1.2 mg or 1.8 mg could leave a patient under-treated.
How to Prepare for the Conversation With Your Care Team
Patients considering this switch will benefit from arriving at their appointment prepared. Bringing the current dulaglutide dose, the most recent HbA1c result, a list of all other diabetes medications, and a summary of any side effects experienced on dulaglutide gives the prescriber the full picture needed to make a safe recommendation.
Specifically ask whether liraglutide is covered at the therapeutically appropriate dose, not just the starter dose. Ask what blood glucose targets to aim for during the titration period and whether any other medications in the regimen need to be adjusted.
Doctronic, which has completed over 22 million AI consultations with 99.2% treatment plan alignment with board-certified physicians, offers 24/7 AI consultations to help patients organize their questions and understand their options before speaking with a prescriber. A video visit with a licensed physician can confirm the transition plan, review renal and cardiovascular factors, and adjust supporting medications as needed, all without waiting weeks for an in-person appointment.
Frequently Asked Questions
No FDA-approved conversion chart exists for switching from dulaglutide to liraglutide. Clinicians rely on pharmacodynamic equivalence studies and individual patient factors to guide the transition. Because the two drugs use different dosing schedules, weekly versus daily, no simple side-by-side milligram comparison is medically accurate or officially endorsed.
Clinicians most commonly bridge dulaglutide 1.5 mg weekly to liraglutide 1.2 to 1.8 mg daily. This range reflects the closest pharmacodynamic overlap based on available studies and prescriber experience. However, the final dose should be confirmed by your doctor based on your HbA1c, tolerability history, and other personal health factors.
Yes. Liraglutide requires a 4-week starter period at 0.6 mg daily regardless of prior GLP-1 experience. This titration step is standard protocol and helps reduce GI side effects. Skipping it is not recommended even if you tolerated dulaglutide well, because the daily dosing pattern of liraglutide can still cause nausea in some patients.
It is possible. Some patients experience slightly different efficacy with liraglutide compared to dulaglutide. Blood glucose monitoring should be more frequent during the first 4 to 8 weeks after switching. Your prescriber may also want to review other diabetes medications in your regimen to ensure your overall treatment plan remains on target.
No. Switching between these medications without medical supervision is not safe. Dosing differences, titration requirements, renal considerations, and potential interactions with other diabetes drugs all require a prescriber's review. Doctronic offers 24/7 AI consultations and affordable $39 video visits to help you prepare for and complete this transition safely.
The Bottom Line
Switching from dulaglutide to liraglutide is a common transition, but it carries real complexity because no standardized conversion table exists and the dosing structures are fundamentally different. Individual variables including renal function, cardiovascular history, HbA1c targets, and adherence patterns all shape the right approach for each patient. Higher dulaglutide doses may not be fully replicated, and a mandatory titration period means your glucose control needs close monitoring during the switch. Doctronic, the first AI legally authorized to practice medicine in Utah, has supported over 22 million AI consultations and can help you prepare for this conversation with your care team. This article is informational and is not a medical diagnosis. Confirm with a licensed clinician, especially for new, worsening, or high-risk symptoms.
Related articles
Get dulaglutide dosing guidance
Chat Now